A Phase II Trial of Poly-ICLC for Low-Grade Gliomas

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

February 8, 2022

Primary Completion Date

January 4, 2024

Study Completion Date

November 15, 2024

Conditions
NF1Low-grade Glioma
Interventions
DRUG

Poly ICLC

Enrolled participants will receive poly-ICLC 20 mcg/kg/dose twice weekly IM (using Monday/Thursday or Tuesday/Friday schedule if possible).

Trial Locations (12)

10016

New York University Medical Center (Site 200), New York

19096

Children's Hospital of Philadelphia (Site 750), Philadelphia

20010

Children's National Medical Center (Site 775), Washington D.C.

30342

Children's Healthcare of Atlanta, Atlanta

35294

The University of Alabama at Birmingham (Site 700), Birmingham

60611

Children's Lurie Hospital, Chicago

Lurie Children's Hospital of Chicago (Site 350), Chicago

60637

University of Chicago (Site 850), Chicago

63110

Washington University - St. Louis (Site 900), St Louis

75235

Childrens Medical Center - Univ. of Texas SW (Site 917), Dallas

90027

Children's Hospital of Los Angeles, Los Angeles

45229-3039

Cincinnati Children's Hospital Medical Center (Site 800), Cincinnati

Sponsors
All Listed Sponsors
collaborator

Children's Healthcare of Atlanta

OTHER

collaborator

Children's Hospital Los Angeles

OTHER

lead

University of Alabama at Birmingham

OTHER